Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Pharming Group N.V (PHAR) Enterprise Value: 2019-2025

Historic Enterprise Value for Pharming Group N.V (PHAR) over the last 5 years, with Sep 2025 value amounting to $984.1 million.

  • Pharming Group N.V's Enterprise Value rose 76.34% to $984.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $978.3 million, marking a year-over-year increase of 76.73%. This contributed to the annual value of $681.3 million for FY2024, which is 9.40% down from last year.
  • Latest data reveals that Pharming Group N.V reported Enterprise Value of $984.1 million as of Q3 2025, which was up 35.89% from $724.2 million recorded in Q2 2025.
  • In the past 5 years, Pharming Group N.V's Enterprise Value ranged from a high of $984.1 million in Q3 2025 and a low of $378.4 million during Q2 2022.
  • For the 3-year period, Pharming Group N.V's Enterprise Value averaged around $714.9 million, with its median value being $724.2 million (2025).
  • As far as peak fluctuations go, Pharming Group N.V's Enterprise Value soared by 394.34% in 2021, and later slumped by 30.78% in 2022.
  • Quarterly analysis of 5 years shows Pharming Group N.V's Enterprise Value stood at $570.1 million in 2021, then surged by 35.77% to $774.0 million in 2022, then fell by 2.86% to $751.9 million in 2023, then decreased by 9.40% to $681.3 million in 2024, then skyrocketed by 76.34% to $984.1 million in 2025.
  • Its Enterprise Value stands at $984.1 million for Q3 2025, versus $724.2 million for Q2 2025 and $568.9 million for Q1 2025.